Sugi Predict

Sugi Predict / Compounds / SCHEMBL25867803

SCHEMBL25867803

SCHEMBL25867803

Cc1cc(NC(C)C)nc(C(F)(F)F)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 2/20 0.43
▸ CYP1A2 P05177 1/20 0.40
▸ TRPM8 Q7Z2W7 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.34
▸ HSP90AB1 P08238 1/20 0.34
▸ CCNE2 O96020 3/20 0.34
▸ CCNE1 P24864 3/20 0.34
▸ CDK2 P24941 3/20 0.34
▸ CDK4 P11802 2/20 0.34
▸ CCND1 P24385 2/20 0.34
▸ HCRTR1 O43613 2/20 0.33
▸ HCRTR2 O43614 2/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HTR2B P41595 1/20 0.32
▸ TLR9 Q9NR96 1/20 0.32
▸ TLR8 Q9NR97 1/20 0.32
▸ HRH4 Q9H3N8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7996776 0.81 TLR7 (0.42) TLR7CYP1A2TRPM8CCNE2CCNE1
SCHEMBL16840726 0.79 NOS3 (0.50) HSP90AA1HSP90AB1HTT
SCHEMBL25083887 0.78 TLR7 (0.40) TLR7CYP1A2TRPM8CCNE2CCNE1
SCHEMBL11981453 0.76 HSP90AA1 (0.46) CYP1A2HSP90AA1HSP90AB1HTT
SCHEMBL12262320 0.75 TRPM8 (0.45) CYP1A2TRPM8NR4A2HRH4
SCHEMBL16608839 0.73 LMNA (0.46) CYP1A2TRPM8HTT
SCHEMBL20145277 0.72 TLR8 (0.47) TLR7CYP1A2HTTTLR8
SCHEMBL20476318 0.72 ALDH1A1 (0.51) CYP1A2TRPM8NR4A2HTTHRH4
SCHEMBL801826 0.72 TRPM8 (0.42) TLR7CYP1A2TRPM8NR4A2TLR9
SCHEMBL8301083 0.72 CYP1A2 (0.51) CYP1A2TRPM8HSP90AA1HSP90AB1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 — — US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A TLR7 3207/4885CYP1A2 4379/4885TRPM8 1438/4885
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A TLR7 1917/4885CYP1A2 3113/4885TRPM8 2144/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R TLR7 2581/4885CYP1A2 4602/4885TRPM8 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.